SCHEMBL4672222

SCHEMBL4672222

Cc1ccc(Cc2cc[nH]c2C(=O)/C=C(\O)C(=O)O)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.37
CTBP2 P56545 1/20 0.34
PDE3B Q13370 1/20 0.34
PDE3A Q14432 1/20 0.34
KDM4E B2RXH2 2/20 0.33
HSP90AA1 P07900 1/20 0.32
LMNA P02545 3/20 0.32
PPARG P37231 1/20 0.32
PPARA Q07869 1/20 0.32
SMN1; SMN2 Q16637 2/20 0.31
NPSR1 Q6W5P4 2/20 0.30
MEN1 O00255 1/20 0.30
KMT2A Q03164 1/20 0.30
ATM Q13315 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
ALDH1A1 P00352 2/20 0.30
MAPT P10636 1/20 0.30
THRB P10828 1/20 0.30
HPGD P15428 1/20 0.30
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4672228 1.00 SRD5A2 (0.37) SRD5A2CTBP2PDE3BPDE3AKDM4E
SCHEMBL4675711 0.87 CYP1A2 (0.38) PPARGPPARASMN1; SMN2MEN1KMT2A
SCHEMBL4675707 0.87 CYP1A2 (0.38) PPARGPPARASMN1; SMN2MEN1KMT2A
SCHEMBL4677906 0.87 KMT2A (0.45) LMNAPPARGPPARASMN1; SMN2KMT2A
SCHEMBL4677900 0.87 KMT2A (0.45) LMNAPPARGPPARASMN1; SMN2KMT2A
SCHEMBL4678128 0.86 HTR6 (0.35) TDP1ALDH1A1
SCHEMBL4673320 0.86 CTBP2 (0.34) CTBP2KDM4EHSP90AA1LMNAPPARG
SCHEMBL4673314 0.86 CTBP2 (0.34) CTBP2KDM4EHSP90AA1LMNAPPARG
SCHEMBL4678126 0.86 HTR6 (0.35) TDP1ALDH1A1
SCHEMBL4672681 0.86 ALDH1A1 (0.40) CTBP2PPARGPPARASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 SRD5A2 371/4885CTBP2 3183/4885PDE3B 4003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.